<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608318</url>
  </required_header>
  <id_info>
    <org_study_id>CLL17</org_study_id>
    <secondary_id>2019-003854-99</secondary_id>
    <nct_id>NCT04608318</nct_id>
  </id_info>
  <brief_title>Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)</brief_title>
  <acronym>CLL17</acronym>
  <official_title>A Phase 3 Multicentre, Randomized, Prospective, Open-label Trial of Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German CLL Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordic CLL Study Group (NCLLSG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Group for Clinical Cancer Research (SAKK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo Español de Leucemia Linfocítica Crónica (GELLC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Israeli CLL Study Group (ICLLSG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German CLL Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy of continuous ibrutinib monotherapy with&#xD;
      fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax by&#xD;
      measuring progression-free survival (PFS) in patients with previously untreated CLL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator-assessed progression-free survival (PFS)</measure>
    <time_frame>Up to 80 month</time_frame>
    <description>Time from randomization to the first occurrence of progression or relapse (determined using standard iwCLL guidelines), or death from any cause, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of undetectable minimal residual disease (uMRD) in peripheral blood (PB) and bone marrow (BM)</measure>
    <time_frame>At final restaging (RE): 18 months after start of treatment and additional BM assessment approx. 12 months after RE</time_frame>
    <description>Undetectable MRD (uMRD) is defined as &lt;10-4 (=1 CLL-cell per 10,000 leukocytes analyzed).The uMRD rate is defined as the proportion of patients having achieved uMRD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD levels in PB at different time points</measure>
    <time_frame>Up to 80 month</time_frame>
    <description>MRD is defined as the number of CLL-cells that can be detected in peripheral blood (PB) or bone marrow (BM). MRD values will be categorized into negative (&lt;10-4) and positive (≥10-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>At final restaging (RE): 18 months after start of treatment</time_frame>
    <description>Proportion of patients having achieved a complete response (CR), a CR with incomplete recovery of the bone marrow (CRi), or a partial response (PR) as best response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR/CRi rate</measure>
    <time_frame>At final restaging (RE): 18 months after start of treatment</time_frame>
    <description>Proportion of patients having achieved a CR or CRi as best response (= number of patients with best response CR or CRi divided by the number of the intention-to-treat population (ITT) population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of safety parameters such as adverse events (AE) and adverse events of particular/special interest (AEPI/AESI)</measure>
    <time_frame>Up to 80 month</time_frame>
    <description>Type, frequency, severity and relationship to study treatment.of AEs and AEPIs/AESIs</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">897</enrollment>
  <condition>Chronic Lymphoid Leukemia</condition>
  <arm_group>
    <arm_group_label>I (Ibrutinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib p.o. will be administered until occurrence of unacceptable toxicity, progression of CLL or end of trial, whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VG (Obinutuzumab + Venetoclax)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 cycles (q 28d): Obinutuzumab i.v. + Venetoclax p.o. will be administered for 6 cycles, followed by 6 additional cycles of Venetoclax alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI (Venetoclax + Ibrutinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 cycles (q 28d): Ibrutinib p.o. + Venetoclax p.o. will be administered for a total of 12 cycles with a prior Ibrutinib monotherapy lead-in of 3 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Cycles 1 - X: 420 mg daily, d1-28 p.o.</description>
    <arm_group_label>I (Ibrutinib)</arm_group_label>
    <arm_group_label>VI (Venetoclax + Ibrutinib)</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Arm VG&#xD;
Cycle 1: 20 mg (2 tabl. at 10 mg), d22-28 p.o.&#xD;
Cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28 p.o.&#xD;
Cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28 p.o.&#xD;
Arm VI&#xD;
Cycle 4: 20 mg (2 tabl. at 10 mg), d1-7; 50 mg (1 tabl. at 50 mg), d8-14; 100 mg (1 tabl. at 100 mg), d15-21; 200 mg (2 tabl. at 100 mg), d22-28 p.o.&#xD;
Cycles 5-15: 400 mg (4 tabl. at 100 mg), d1-28 p.o.</description>
    <arm_group_label>VG (Obinutuzumab + Venetoclax)</arm_group_label>
    <arm_group_label>VI (Venetoclax + Ibrutinib)</arm_group_label>
    <other_name>ABT-199, Venclyxto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Cycle 1: (100 mg, d1 + 900 mg, d2) or 1000 mg, d1; 1000 mg, d8 + d15 i.v. Cycle 2 - 6: 1000 mg, d1 i.v.</description>
    <arm_group_label>VG (Obinutuzumab + Venetoclax)</arm_group_label>
    <other_name>GA101, Gazyvaro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented CLL requiring treatment according to iwCLL criteria.&#xD;
&#xD;
          2. Age at least 18 years.&#xD;
&#xD;
          3. Life expectancy ≥ 6 months.&#xD;
&#xD;
          4. Ability and willingness to provide written informed consent and to adhere to the study&#xD;
             visit schedule and other protocol requirements.&#xD;
&#xD;
          5. Adequate bone marrow function independent of growth factor or transfusion support&#xD;
             within 2 weeks of screening initiation as follows, unless cytopenia is due to CLL:&#xD;
&#xD;
               1. Absolute neutrophil count ≥ 1.0 × 109/L&#xD;
&#xD;
               2. Platelet counts ≥ 30 × 109/L; in cases of thrombocytopenia clearly due to CLL&#xD;
                  (per the discretion of the investigator), platelet count should be ≥ 10 × 109/L&#xD;
&#xD;
               3. Total haemoglobin ≥ 9 g/dL (without transfusion support, unless anaemia is due to&#xD;
                  CLL)&#xD;
&#xD;
          6. GFR &gt;30ml/min directly measured with 24hr urine collection, calculated according to&#xD;
             the modified formula of Cockcroft and Gault (for men: GFR ≈ ((140 - age) x&#xD;
             bodyweight)/ (72 x creatinine), for women x 0, 85) or an equally accurate method.&#xD;
&#xD;
             a. For patients with creatinine values within the normal range the calculation of the&#xD;
             clearance is not necessary. Dehydrated patients with an estimated creatinine clearance&#xD;
             less than 30 ml/min may be eligible if a repeat estimate after adequate hydration is &gt;&#xD;
             30 ml/min.&#xD;
&#xD;
          7. Adequate liver function as indicated by a total bilirubin ≤ 2 x, AST/ ALT ≤ 2.5 x the&#xD;
             institutional ULN value, unless directly attributable to the patient's CLL or to&#xD;
             Gilbert's Syndrome.&#xD;
&#xD;
          8. Negative serological testing for hepatitis B (HbsAg negative and anti-HBc negative;&#xD;
             patients positive for anti-HBc may be included if PCR for HBV DNA is negative and&#xD;
             HBV-DNA PCR is performed every month until 12 months after last treatment cycle),&#xD;
             negative testing for hepatitis C RNA within 6 weeks prior to registration for study&#xD;
             screening (i.e. PCR only required when serology was positive).&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group Performance Status (ECOG) performance status 0-2.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Any prior CLL-specific therapies (except corticosteroid treatment administered due to&#xD;
             necessary immediate intervention; within the last 10 days before start of study&#xD;
             treatment, only dose equivalents up to 20 mg prednisolone are permitted).&#xD;
&#xD;
          2. Transformation of CLL (Richter transformation). When Richter transformation is&#xD;
             suspected, PET-CT and/or biopsy should be performed to rule out transformation.&#xD;
&#xD;
          3. Patients with a history of PML.&#xD;
&#xD;
          4. An individual organ/ system impairment score of 4 as assessed by the CIRS definition&#xD;
             limiting the ability to receive the study treatment or any other life-threatening&#xD;
             illness, medical condition or organ system dysfunction that, in the investigator´s&#xD;
             opinion, could compromise the patients' safety or interfere with the absorption or&#xD;
             metabolism of the study drugs (e.g. inability to swallow tablets or impaired&#xD;
             resorption in the gastrointestinal tract).&#xD;
&#xD;
          5. Malignancies other than CLL currently requiring systemic therapies, not being treated&#xD;
             with curative intent before (unless the malignant disease is in a stable remission due&#xD;
             to the discretion of the treating physician or showing signs of progression after&#xD;
             curative treatment.&#xD;
&#xD;
          6. Uncontrolled or active infection.&#xD;
&#xD;
          7. Patients with known infection with human immunodeficiency virus (HIV).&#xD;
&#xD;
          8. Requirement of therapy with strong CYP3A4 and CYP3A5 inhibitors/ inducers (incl. up to&#xD;
             7 days prior to study treatment start).&#xD;
&#xD;
          9. Anticoagulant therapy with warfarin or phenprocoumon, (alternative anticoagulation is&#xD;
             allowed (e.g. DOACs), but patients must be properly informed about the potential risk&#xD;
             of bleeding under treatment with ibrutinib).&#xD;
&#xD;
         10. History of stroke or intracranial hemorrhage within 6 months prior to registration for&#xD;
             study screening.&#xD;
&#xD;
         11. Known bleeding disorders&#xD;
&#xD;
         12. Child B / C liver cirrhosis&#xD;
&#xD;
         13. Use of investigational agents which might interfere with the study drug within 28 days&#xD;
             prior to registration for study screening.&#xD;
&#xD;
         14. Vaccination with live vaccines 28 days prior to registration for study screening.&#xD;
&#xD;
         15. Major surgery less than 30 days before start of study treatment.&#xD;
&#xD;
         16. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal&#xD;
             antibodies, known sensitivity or allergy to murine products.&#xD;
&#xD;
         17. Known hypersensitivity to any active substance or to any of the excipients of one of&#xD;
             the drugs used in the trial.&#xD;
&#xD;
         18. Pregnant women and nursing mothers (a negative pregnancy test is required for all&#xD;
             women of childbearing potential within 7 days before start of study treatment; further&#xD;
             pregnancy testing will be performed monthly).&#xD;
&#xD;
         19. Fertile men or women of childbearing potential unless:&#xD;
&#xD;
               1. surgically sterile or ≥ 2 years after the onset of menopause&#xD;
&#xD;
               2. willing to use two methods of reliable contraception including one highly&#xD;
                  effective contraceptive method (Pearl Index &lt;1) and one additional effective&#xD;
                  (barrier) method during study treatment and for 18 months after the end of study&#xD;
                  treatment.&#xD;
&#xD;
         20. Legal incapacity.&#xD;
&#xD;
         21. Prisoners or subjects who are institutionalized by regulatory or court order.&#xD;
&#xD;
         22. Persons who are in dependence to the sponsor or an investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Othman Al-Sawaf, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>German CLL Study Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Othman Al-Sawaf, Dr. med.</last_name>
    <phone>+49 221 478 88220</phone>
    <email>othman.al-sawaf@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie &amp; Onkologie</name>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.dcllsg.de/en/trial/cll17/index.php</url>
    <description>Click here for more information about this study: CLL17 (German CLL Study Group)</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

